The treatment outcomes and dose de‐escalation of desloratadine up‐dosing in chronic spontaneous urticaria

The treatment outcomes and dose de‐escalation of desloratadine up‐dosing in chronic... IntroductionChronic urticaria (CU) may seem as a non‐life‐threatening disease, but in reality, it is severe and often debilitating especially due to the itch. It may lead to the loss of both the social life and work of the patients. Chronic spontaneous urticaria (CSU) is characterized by the spontaneous appearance of widespread edematous, pruritic wheals surrounded by a red flare that lasts ≥6 weeks and can recur. CSU is a challenge in regard to treatment. Current international guidelines propose that second‐generation non‐sedating antihistamines constitute the first line of treatment for urticaria, whether acute or chronic. The European Academy of Allergology and Clinical Immunology/Global Allergy and Asthma European Network/European Dermatology Forum/World Allergy Organization (EAACI/GA2LEN/EDF/WAO) guidelines state that before considering an alternative treatment, a trial of second‐generation antihistamines at doses up to four times indicated is warranted for patients who do not respond to standard doses when the potential benefits outweigh any risks. In addition, increased antihistamine doses improve patient quality of life without increasing somnolence. Once this disease is completely controlled, however, the optimal method for reducing the dose of antihistamine has not been determined.Desloratadine is a non‐sedating, second‐generation H1‐antihistamine. Overall, the quality of evidence is high for desloratadine being safe http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Dermatology Wiley

The treatment outcomes and dose de‐escalation of desloratadine up‐dosing in chronic spontaneous urticaria

Loading next page...
 
/lp/wiley/the-treatment-outcomes-and-dose-de-escalation-of-desloratadine-up-ksgMVmGDU0
Publisher
Wiley
Copyright
International Journal of Dermatology © 2018 International Society of Dermatology
ISSN
0011-9059
eISSN
1365-4632
D.O.I.
10.1111/ijd.13919
Publisher site
See Article on Publisher Site

Abstract

IntroductionChronic urticaria (CU) may seem as a non‐life‐threatening disease, but in reality, it is severe and often debilitating especially due to the itch. It may lead to the loss of both the social life and work of the patients. Chronic spontaneous urticaria (CSU) is characterized by the spontaneous appearance of widespread edematous, pruritic wheals surrounded by a red flare that lasts ≥6 weeks and can recur. CSU is a challenge in regard to treatment. Current international guidelines propose that second‐generation non‐sedating antihistamines constitute the first line of treatment for urticaria, whether acute or chronic. The European Academy of Allergology and Clinical Immunology/Global Allergy and Asthma European Network/European Dermatology Forum/World Allergy Organization (EAACI/GA2LEN/EDF/WAO) guidelines state that before considering an alternative treatment, a trial of second‐generation antihistamines at doses up to four times indicated is warranted for patients who do not respond to standard doses when the potential benefits outweigh any risks. In addition, increased antihistamine doses improve patient quality of life without increasing somnolence. Once this disease is completely controlled, however, the optimal method for reducing the dose of antihistamine has not been determined.Desloratadine is a non‐sedating, second‐generation H1‐antihistamine. Overall, the quality of evidence is high for desloratadine being safe

Journal

International Journal of DermatologyWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off